<DOC>
	<DOC>NCT00195754</DOC>
	<brief_summary>The purpose of this study is to determine if long-term treatment, up to 1 year, with Depakote ER is safe in the reduction of occurrence of migraine headaches in adolescents.</brief_summary>
	<brief_title>A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject and subject's legal representative have voluntarily signed and dated an IRBapproved informed assent form and an IRBapproved informed consent form, respectively, before any studyspecific procedures or tests are performed; The subject was randomized into Study M02488 and either completed the study or prematurely discontinued due to ineffectiveness; and The subject is male or nonpregnant, nonlactating female Exclusion Criteria Female, of childbearing potential, and not using an effective method of birth control (e.g., total sexual abstinence or contraceptives). Experienced a serious adverse event in Study M02488 which the investigator considered "possibly" or "probably related" to study drug; or In the investigator's opinion, longterm treatment with Depakote ER for migraine prophylaxis is contraindicated. For any reason, subject is considered by the investigator to be an unsuitable candidate to receive divalproex sodium or to participate in this study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Migraines</keyword>
	<keyword>Depakote ER</keyword>
	<keyword>divalproex sodium</keyword>
</DOC>